Cambridge Research Biochemicals (CRB), a supplier of peptide and antibody research reagents, has licensed new fluorescent dyes from the University of Edinburgh that enhance live-cell imaging.
Cambridge Research Biochemicals (CRB), a UK-based supplier of research reagents, namely peptides and antibodies, signed a license agreement on Aug. 31, 2017 with Edinburgh Innovations, the commercialization arm of the University of Edinburgh, to use new fluorescent dyes developed by a research team at the university to label custom-made and catalogue peptides.
These dyes, which are activatable fluorophores, have been specially developed to enable fluorogenic labelling of peptides for enhanced live-cell imaging. They offer advantages from a synthesis perspective and for the end-user scientist. The former is because the dye is preconjugated to an amino acid, tryptophan, facilitating direct inclusion into the peptide sequence rather than post-purification labelling. This minimizes the number of reaction steps and, therefore, the time taken to prepare the labelled product, according to CRB. The latter is due to high signal-to-noise ratios with increased sensitivity, which enables use of the material in small concentrations, reducing potential adverse effects and facilitating clinical translation.
This agreement is significant to CRB, which has supplied the University of Edinburgh for years as a specialist custom research organization. The company is now seeking a more collaborative approach. The agreement will enable CRB to expand its current dye portfolio, offering a greater selection of products and increased flexibility on its labelling strategy. It will also permit expansion of the Discovery Peptides catalogue, which was officially launched earlier in 2017 and which includes a new range of pre-labelled antimicrobial peptides.
The research team at the university worked in collaboration with academic partners at the University of Barcelona, the Institute for Research in Biomedicine Barcelona, and the University of Manchester to co-invent the technology.
Source: Cambridge Research Biochemicals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.